Erratum: Cost elements to be considered in estimates for microcosting studies in peritoneal dialysis (PD) therapy in Latin AmericaIn the article “Cost elements to be considered in estimates for microcosting studies in peritoneal dialysis (PD) therapy in Latin America”, with DOI https://doi.org/10.1590/2175-8239-JBN-2025-0202en, published in the Brazilian Journal of Nephrology, 48(2):e20250202, 2026, on page 13:
Where it reads:
We emphasize that the use of medications directly associated with CKD treatment — such as erythropoietin, phosphorus and iron chelators, and, less frequently, vitamin D analogues — is considered essential to PD therapy.
Editorial Responsibility
Editor-in-chief: Thyago Proença de Moraes https://orcid.org/0000-0002-2983-3968.
It should read:
We emphasize that the use of medications directly associated with CKD treatment — such as erythropoietin, phosphorus and iron chelators, and, less frequently, vitamin D analogues — they are not considered essential for PD therapy.
Editorial Responsibility
Deputy-Editor: Thyago Proença de Moraes https://orcid.org/0000-0002-2983-3968.
